Dear Editor:

Accumulating data suggest that some variants of Crohn\'s disease (CD) may be consequent to a *Mycobacterium avium* subspecies *paratuberculosis* (MAP) infection. Opportunely, a prospective study (Kalfus, [@B3]) is addressing the therapeutic role of appropriate antimycobacterial antimicrobials in CD. Potential inflammatory bowel disease (IBD) benefits may include identification of a mycobacterial etiology, improvement on current therapies, and possibly prevention.

MAP is inhibited by agents that the scientific community categorizes as anti-inflammatory (Greenstein *et al.,* [@B2]) and immune-modulators. (Krishnan *et al.,* [@B4]) A much-cited 2007 "placebo controlled" trial of anti-MAP antibiotics concluded that there was "no significant role for MAP in the pathogenesis of CD" (Selby *et al.,* [@B5]). Subsequent correspondence dismissed the possible corrupting influence of unanticipated "immune-modulator" anti-MAP inhibition as being "not consistent" with prevailing dogma. This was despite the editorial accompanying the 2007 study emphasizing significant improvement associated with concomitant use of "immune-modulators" (Selby *et al.,* [@B5]).

Disconcertingly, the inclusion criteria in the ongoing study (Kalfus, [@B3]) are essentially identical to the prior "placebo"-controlled study (Selby *et al.,* [@B5]). Both ignore MAP inhibition by "anti-inflammatory" (Greenstein *et al.,* [@B2]) and "immune-modulators." (Krishnan *et al.,* [@B4]) The 2007 study (Selby *et al.,* [@B5]) was designed before relevant MAP inhibition data (Greenstein *et al.,* [@B2]; Krishnan *et al.,* [@B4]) were published. The designers of the study now recruiting (Kalfus, [@B3]) should explain why they ignore unrefuted published data that render their "placebo-controlled" study as flawed as previously (Selby *et al.,* [@B5]).

We suggest that calling the study now recruiting (Kalfus, [@B3]) "placebo-controlled" is unscientific (Greenstein *et al.,* [@B1]). Multiple medications that inhibit infectious agents (Greenstein *et al.,* [@B1]) are permitted in both the "placebo" as well as treated groups. (Greenstein *et al.,* [@B1]). Previously, we have suggested that "add-on studies" is scientifically more accurate than "placebo-controlled" (Greenstein *et al.,* [@B1]).

A consistently flawed study design may yet again be misinterpreted as showing no added efficacy of anti-MAP agents in CD. Consequently, the potential identification of the etiology of IBD as being due to the zoonosis of MAP may irrevocably be lost.
